Domain Therapeutics - A new Name in GPCR Drug Discovery
Complete the form below to unlock access to ALL audio articles.
Domain Therapeutics, a drug discovery company focused on the identification of allosteric modulators of G Protein-Coupled Receptors (GPCRs), previously Faust Pharmaceuticals, has announced that it has adopted a new company name, previously Faust Pharmaceuticals.
Until recently the company has exploited its GPCR technology to build its own pipeline and has now decided to give access to this proprietary platform to companies involved in GPCR drug discovery. In addition, Domain Therapeutics will conduct early development of its products on leading therapeutic indications.
The new name, Domain Therapeutics, also marks a transition from a strategy exclusively oriented towards a single therapeutic area (the diseases of the central nervous system) to a strategy directed towards a family of targets, GPCRs, whatever the indication.
"To our knowledge, there are no other specific technologies available for allosteric modulators," said Pascal Neuville, newly-named CEO of Domain Therapeutics. "Our platform represents therefore a key competitive advantage in an area of huge unmet need."
The technology has been validated on difficult targets including orphan GPCRs and Domain Therapeutics already has a pipeline of products, from hits to preclinical candidates, with excellent IP protection and acting on the most promising targets.
These favorable factors mean that Domain Therapeutics anticipates being able to raise funds and sign a number of collaborations on its technology platform, as well as build partnerships on its products.
